Eli Lilly and Company (LLY) SVP Jeffrey N. Simmons Sells 12,500 Shares of Stock
Eli Lilly and Company (NYSE:LLY) SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $86.46, for a total value of $1,080,750.00. Following the transaction, the senior vice president now directly owns 124,522 shares in the company, valued at approximately $10,766,172.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eli Lilly and Company (LLY) traded down $1.39 during trading hours on Thursday, reaching $86.50. The company’s stock had a trading volume of 4,364,272 shares, compared to its average volume of 3,686,396. Eli Lilly and Company has a 1 year low of $69.66 and a 1 year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $95,475.95, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.77 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the firm posted $0.88 earnings per share. The company’s quarterly revenue was up 9.0% on a year-over-year basis. sell-side analysts expect that Eli Lilly and Company will post 4.21 EPS for the current year.
LLY has been the topic of several research reports. BMO Capital Markets reaffirmed a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research note on Wednesday, August 16th. BidaskClub lowered Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Leerink Swann reaffirmed a “hold” rating on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average target price of $90.25.
A number of large investors have recently added to or reduced their stakes in LLY. Acrospire Investment Management LLC raised its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and during the second quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and during the second quarter worth about $129,000. Willingdon Wealth Management acquired a new stake in shares of Eli Lilly and during the third quarter worth about $138,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of Eli Lilly and during the third quarter worth about $142,000. 76.42% of the stock is currently owned by hedge funds and other institutional investors.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related stocks with our FREE daily email newsletter.